<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998971</url>
  </required_header>
  <id_info>
    <org_study_id>CR103015</org_study_id>
    <secondary_id>54767414MMY1001</secondary_id>
    <secondary_id>2013-003491-12</secondary_id>
    <nct_id>NCT01998971</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and dose regimen of
      daratumumab when administered in combination with various treatment regimens for the
      treatment of multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (identity of assigned study drug will be known) study to evaluate the
      safety, tolerability, and dose of daratumumab when administered in combination with various
      treatment regimens for different settings of multiple myeloma. The various treatment regimens
      to be combined with daratumumab in this study include Velcade-dexamethasone (VD),
      Velcade-melphalan-prednisone (VMP), Velcade-thalidomide-dexamethasone (VTD),
      pomalidomide-dexamethasone (Pom-dex), carfilzomib-dexamethasone (CFZ-dex) and
      carfilzomib-lenalidomide-dexamethasone (KRd). Approximately 250 patients (approximately 12
      subjects per VTD and VMP backbone treatment regimen, 6 for the VD regimen, up to 100 subjects
      in the Pom-dex regimen, 80 for the CFZ-dex regimen [10 subjects will receive a single-dose of
      daratumumab and the remaining subjects will receive a split-dose of daratumumab], and up to
      40 for the KRd regimen) will be enrolled in this study.The study will consist of screening,
      treatment, and follow-up phases. Treatment will extend to either the planned treatment
      duration for a maximum of 1 year (in Velcade-dexamethasone, Velcade-melphalan-prednisone,
      Velcade-thalidomide-dexamethasone regimens and KRd regimens), or until disease progression
      (in the Pom-dex and CFZ-dex regimen). Follow-up will continue until the study ends
      (approximately 15 months after the last patient receives the first dose of daratumumab).
      Serial pharmacokinetic (study of what a drug does to the body) blood samples will be
      collected. Clinical efficacy outcomes and safety will be monitored throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 18, 2014</start_date>
  <completion_date type="Anticipated">June 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants affected by dose-limiting toxicities</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration of daratumumab</measure>
    <time_frame>Up to post-treatment visit Week 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with generation of antibodies to daratumumab</measure>
    <time_frame>Up to post-treatment visit Week 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-dexamethasone (VD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Administered by intravenous infusion in combination with the applicable backbone treatment.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Administered subcutaneously in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Administered intravenously or orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Administered intravenously or orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Administered in prophylactic doses by mouth in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Administered intravenously in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of symptomatic multiple myeloma and measurable secretory disease

          -  For carfilzomib-lenalidomide-dexamethasone (KRd) regimen: newly diagnosed myeloma. For
             carfilzomib-dexamethasone (CFZ-dex) regimen: relapsed or refractory disease

          -  Eastern Cooperative Oncology Group performance status score of 0, 1, or 2

          -  Pretreatment clinical laboratory values must meet protocol-defined parameters during
             the screening phase

        Exclusion Criteria:

          -  Previously received daratumumab or other anti-CD38 therapies

          -  Diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance,
             smoldering multiple myeloma, Waldenstr√∂m's disease, or other conditions in which IgM
             M-protein is present in the absence of a clonal plasma cell infiltration with lytic
             bone lesions

          -  Peripheral neuropathy or neuropathic pain Grade 2 or higher

          -  Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years
             of study start

          -  Exhibiting clinical signs of meningeal involvement of multiple myeloma

          -  Known chronic obstructive pulmonary disease, persistent asthma, or a history of asthma
             within 2 years

          -  Seropositive for human immunodeficiency virus, hepatitis B, or hepatitis C

          -  Any concurrent medical or psychiatric condition or disease that is likely to interfere
             with the study procedures or results, or that in the opinion of the investigator,
             would constitute a hazard for participating in this study

          -  Clinically significant cardiac disease

          -  Plasma cell leukemia or POEMS (polyneuropathy, organomegaly, endocrinopathy,
             monoclonal protein, and skin changes) syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>JNJ-54767414</keyword>
  <keyword>Velcade-dexamethasone</keyword>
  <keyword>Velcade-melphalan-prednisone</keyword>
  <keyword>Velcade-thalidomide-dexamethasone</keyword>
  <keyword>Pomalidomide-dexamethasone</keyword>
  <keyword>Carfilzomib-dexamethasone</keyword>
  <keyword>Carfilzomib-lenalidomide-dexamethasone</keyword>
  <keyword>Anti-CD38 Monoclonal Antibody</keyword>
  <keyword>Immunomodulatory drug</keyword>
  <keyword>IMiD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

